Loading…
Medinatura New Mexico, Inc. received a warning letter for current Good Manufacturing Practice (CGMP) violations in the production of finished pharmaceutical drugs, specifically homeopathic products. During a May 2025 inspection, the FDA identified critical failures in component testing, including inadequate identity testing of incoming materials and active pharmaceutical ingredients, as well as failure to validate the reliability of suppliers' test analyses at appropriate intervals as required by 21 CFR 211.84. The firm's testing procedures were limited and relied heavily on supplier certificates of analysis without establishing their reliability, resulting in the determination that the drug products were adulterated under the Federal Food, Drug, and Cosmetic Act.